
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6837424/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	AIDS at 40 th : The progress of HIV treatment in Japan. Global Health & Medicine, 2022, 4, 1-8.	1.4	1
2	A four-year observation of HIV and sexually transmitted infections among men who have sex with men before and during pre-exposure prophylaxis in Tokyo. Journal of Infection and Chemotherapy, 2022, 28, 762-766.	1.7	8
3	ldentification of asymptomatic Entamoeba histolytica infection by a serological screening test: A cross-sectional study of an HIV-negative men who have sex with men cohort in Japan. PLoS Neglected Tropical Diseases, 2022, 16, e0009793.	3.0	4
4	Impact of Micropolymorphism Outside the Peptide Binding Groove in the Clinically Relevant Allele HLA-C*14 on T Cell Responses in HIV-1 Infection. Journal of Virology, 2022, 96, e0043222.	3.4	2
5	Characteristics of 2-drug regimen users living with HIV-1 in a real-world setting: A large-scale medical claim database analysis in Japan. PLoS ONE, 2022, 17, e0269779.	2.5	0
6	Clinical Features and Gut Microbiome of Asymptomatic <i>Entamoeba histolytica</i> Infection. Clinical Infectious Diseases, 2021, 73, e3163-e3171.	5.8	12
7	Effect of Difference in Consensus Sequence between HIV-1 Subtype A/E and Subtype B Viruses on Elicitation of Gag-Specific CD8 ⁺ T Cells and Accumulation of HLA-Associated Escape Mutations. Journal of Virology, 2021, 95, .	3.4	4
8	Impact of Human Leukocyte Antigen-Associated Polymorphisms on Variability of HIV-1 Accessory and Regulatory Proteins. AIDS Research and Human Retroviruses, 2021, 37, 962-966.	1.1	1
9	Influence of maternal use of tenofovir disoproxil fumarate or zidovudine in Vietnamese pregnant women with HIV on infant growth, renal function, and bone health. PLoS ONE, 2021, 16, e0250828.	2.5	3
10	Performance of an enzyme-linked immunosorbent-based serological assay for Entamoeba histolytica: Comparison with an indirect immunofluorescence assay using stored frozen samples. Journal of Infection and Chemotherapy, 2021, 27, 736-739.	1.7	3
11	Anal human papillomavirus infection and its relationship with abnormal anal cytology among MSM with or without HIV infection in Japan. Scientific Reports, 2021, 11, 19257.	3.3	5
12	Evaluation of SARS-CoV-2 Antibodies and the Impact of COVID-19 on the HIV Care Continuum, Economic Security, Risky Health Behaviors, and Mental Health Among HIV-Infected Individuals in Vietnam. AIDS and Behavior, 2021, , 1.	2.7	5
13	Long-term weight gain after initiating combination antiretroviral therapy in treatment-naÃ ⁻ ve Asian people living with human immunodeficiency virus. International Journal of Infectious Diseases, 2021, 110, 21-28.	3.3	19
14	Collaboration of a detrimental HLA-B*35:01 allele with HLA-A*24:02 in co-evolution of HIV-1 with T-cells leading to poorer clinical outcomes. Journal of Virology, 2021, 95, e0125921.	3.4	2
15	The patient voice: a survey of worries and anxieties during health system transition in HIV services in Vietnam. BMC International Health and Human Rights, 2020, 20, 1.	2.5	23
16	Role of Escape Mutant-Specific T Cells in Suppression of HIV-1 Replication and Coevolution with HIV-1. Journal of Virology, 2020, 94, .	3.4	5
17	Safety and efficacy of reduced-dose pentamidine as second-line treatment for HIV-related pneumocystis pneumonia. Journal of Infection and Chemotherapy, 2020, 26, 1192-1197.	1.7	2
18	Seroprevalence of <i>Entamoeba histolytica</i> at a voluntary counselling and testing centre in Tokyo: a cross-sectional study. BMJ Open, 2020, 10, e031605.	1.9	10

#	Article	IF	CITATIONS
19	Review on the molecular epidemiology of sexually acquired hepatitis C virus infection in the Asiaâ€Pacific region. Journal of the International AIDS Society, 2020, 23, e25618.	3.0	4
20	Utility of the Rapid Antigen Detection Test E. histolytica Quik Chek for the Diagnosis of Entamoeba histolytica Infection in Nonendemic Situations. Journal of Clinical Microbiology, 2020, 58, .	3.9	5
21	Impaired ability of Nef to counteract SERINC5 is associated with reduced plasma viremia in HIV-infected individuals. Scientific Reports, 2020, 10, 19416.	3.3	8
22	Fullâ€genome analysis of hepatitis C virus in HIVâ€coinfected hemophiliac Japanese patients. Hepatology Research, 2020, 50, 763-769.	3.4	1
23	Two cases of endoscopically diagnosed amebic colitis treated with paromomycin monotherapy. PLoS Neglected Tropical Diseases, 2020, 14, e0008013.	3.0	4
24	Dyslipidemia and cardiovascular disease in Vietnamese people with HIV on antiretroviral therapy. Global Health & Medicine, 2020, 2, 39-43.	1.4	6
25	Mortality and causes of death in people living with HIV in the era of combination antiretroviral therapy compared with the general population in Japan. Aids, 2020, 34, 913-921.	2.2	33
26	T-cell responses to sequentially emerging viral escape mutants shape long-term HIV-1 population dynamics. PLoS Pathogens, 2020, 16, e1009177.	4.7	4
27	Pathogenesis, clinical course, and recent issues in HIV-1-infected Japanese hemophiliacs: a three-decade follow-up. Global Health & Medicine, 2020, 2, 9-17.	1.4	6
28	Nucleos(t)ide reverse transcriptase inhibitor-sparing regimens in the era of standard 3-drug combination therapies for HIV-1 infection. Global Health & Medicine, 2020, 2, 384-387.	1.4	1
29	The Role of Neurosurgeons for the Diagnostics of Central Nervous System Lesions in HIV-positive Patients. Japanese Journal of Neurosurgery, 2020, 29, 291-296.	0.0	0
30	Prevalence and incidence of HIV-1 infection in a community-based men who have sex with men (MSM) cohort in Ulaanbaatar, Mongolia. Global Health & Medicine, 2020, 2, 33-38.	1.4	1
31	Title is missing!. , 2020, 16, e1009177.		0
32	Title is missing!. , 2020, 16, e1009177.		0
33	Title is missing!. , 2020, 16, e1009177.		0
34	Title is missing!. , 2020, 16, e1009177.		0
35	Comment on: Tenofovir DF/emtricitabine/rilpivirine as HIV post-exposure prophylaxis: results from a multicentre prospective study. Journal of Antimicrobial Chemotherapy, 2019, 74, 3402-3403.	3.0	1
36	Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in Asian participants with human immunodeficiency virus 1 infection: A sub-analysis of phase 3 clinical trials. HIV Research and Clinical Practice, 2019, 20, 73-81.	1.1	7

#	Article	IF	CITATIONS
37	Effective Suppression of HIV-1 Replication by Cytotoxic T Lymphocytes Specific for Pol Epitopes in Conserved Mosaic Vaccine Immunogens. Journal of Virology, 2019, 93, .	3.4	26
38	CCR5AS lncRNA variation differentially regulates CCR5, influencing HIV disease outcome. Nature Immunology, 2019, 20, 824-834.	14.5	87
39	Identification of Immunodominant HIV-1 Epitopes Presented by HLA-C*12:02, a Protective Allele, Using an Immunopeptidomics Approach. Journal of Virology, 2019, 93, .	3.4	11
40	Combination of Clindamycin and Azithromycin as Alternative Treatment for Toxoplasma gondii Encephalitis. Emerging Infectious Diseases, 2019, 25, 841-843.	4.3	22
41	Short Communication: A Quantitative System for Monitoring Blood-Circulating Viral Protein R of Human Immunodeficiency Virus-1 Detected a Possible Link with Pathogenic Indices. AIDS Research and Human Retroviruses, 2019, 35, 660-663.	1.1	8
42	Molecular epidemiology of acute HCV infection in HIV–positive patients from Hong Kong, Taipei, Tokyo. Liver International, 2019, 39, 1044-1051.	3.9	13
43	High prevalence and incidence of rectal ChlamydiaÂinfection among men who have sex with men in Japan. PLoS ONE, 2019, 14, e0220072.	2.5	11
44	Full-Genome Analysis of Hepatitis C Virus in Japanese and Non-Japanese Patients Coinfected With HIV-1 in Tokyo. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 350-357.	2.1	8
45	Broad Recognition of Circulating HIV-1 by HIV-1-Specific Cytotoxic T-Lymphocytes with Strong Ability to Suppress HIV-1 Replication. Journal of Virology, 2019, 93, .	3.4	15
46	Tenofovir nephrotoxicity among Asians living with HIV: review of the literature. Global Health & Medicine, 2019, 1, 88-94.	1.4	6
47	Case Report: Acute Amebic Colitis Triggered by Colonoscopy: Exacerbation of Asymptomatic Chronic Infection with Entamoeba histolytica Accompanied by Dysbiosis. American Journal of Tropical Medicine and Hygiene, 2019, 101, 1384-1387.	1.4	3
48	Incomplete Recovery of CD4 Cell Count, CD4 Percentage, and CD4/CD8 Ratio in Patients With Human Immunodeficiency Virus Infection and Suppressed Viremia During Long-term Antiretroviral Therapy. Clinical Infectious Diseases, 2018, 67, 927-933.	5.8	34
49	Tenofovir disoproxil fumarate co-administered with lopinavir/ritonavir is strongly associated with tubular damage and chronic kidney disease. Journal of Infection and Chemotherapy, 2018, 24, 549-554.	1.7	12
50	Spectral domain optical coherence tomography and fundus autofluorescence findings in cytomegalovirus retinitis in HIV-infected patients. Japanese Journal of Ophthalmology, 2018, 62, 373-389.	1.9	9
51	Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection. Gut, 2018, 67, 362-371.	12.1	144
52	Time to development of ocular syphilis after syphilis infection. Journal of Infection and Chemotherapy, 2018, 24, 75-77.	1.7	14
53	Cumulative exposure of TDF is associated with kidney tubulopathy whether it is currently used or discontinued. Aids, 2018, 32, 179-188.	2.2	12
54	HLA Class I-Mediated HIV-1 Control in Vietnamese Infected with HIV-1 Subtype A/E. Journal of Virology, 2018, 92, .	3.4	16

#	Article	IF	CITATIONS
55	Increased risk of non-AIDS-defining cancers in Asian HIV-infected patients: a long-term cohort study. BMC Cancer, 2018, 18, 1066.	2.6	27
56	Impact of a single HLA-A*24:02-associated escape mutation on the detrimental effect of HLA-B*35:01 in HIV-1 control. EBioMedicine, 2018, 36, 103-112.	6.1	10
57	CD8+ T cells specific for conserved, cross-reactive Gag epitopes with strong ability to suppress HIV-1 replication. Retrovirology, 2018, 15, 46.	2.0	37
58	Usefulness of Automated Latex Turbidimetric Rapid Plasma Reagin Test for Diagnosis and Evaluation of Treatment Response in Syphilis in Comparison with Manual Card Test: a Prospective Cohort Study. Journal of Clinical Microbiology, 2018, 56, .	3.9	11
59	Identification of two unique naturally occurring Vpr sequence polymorphisms associated with clinical parameters in HIVâ€1 chronic infection. Journal of Medical Virology, 2017, 89, 123-129.	5.0	5
60	Protease inhibitor-associated bone mineral density loss is related to hypothyroidism and related bone turnover acceleration. Journal of Infection and Chemotherapy, 2017, 23, 259-264.	1.7	1
61	Effect of Tenofovir Disoproxil Fumarate on Incidence of Chronic Kidney Disease and Rate of Estimated Glomerular Filtration Rate Decrement in HIV-1–Infected Treatment-NaÃ⊽ve Asian Patients: Results from 12-Year Observational Cohort. AIDS Patient Care and STDs, 2017, 31, 105-112.	2.5	42
62	Lifelong Prophylaxis With Trimethoprim-Sulfamethoxazole for Prevention of Outbreak of Pneumocystis jirovecii Pneumonia in Kidney Transplant Recipients. Transplantation Direct, 2017, 3, e151.	1.6	21
63	Accumulation of Pol Mutations Selected by HLA-B*52:01-C*12:02 Protective Haplotype-Restricted Cytotoxic T Lymphocytes Causes Low Plasma Viral Load Due to Low Viral Fitness of Mutant Viruses. Journal of Virology, 2017, 91, .	3.4	17
64	Prevalence and factors associated with chronic kidney disease and end-stage renal disease in HIV-1-infected Asian patients in Tokyo. Scientific Reports, 2017, 7, 14565.	3.3	16
65	Potential for immune-driven viral polymorphisms to compromise antiretroviral-based preexposure prophylaxis for prevention of HIV-1 infection. Aids, 2017, 31, 1935-1943.	2.2	7
66	Factors associated with pre-treatment HIV RNA: application for the use of abacavir and rilpivirine as the first-line regimen for HIV-infected patients in resource-limited settings. AIDS Research and Therapy, 2017, 14, 27.	1.7	0
67	Underestimated Amoebic Appendicitis among HIV-1-Infected Individuals in Japan. Journal of Clinical Microbiology, 2017, 55, 313-320.	3.9	11
68	Longâ€ŧerm viral suppression and immune recovery during firstâ€ŀine antiretroviral therapy: a study of an HIVâ€infected adult cohort in Hanoi, Vietnam. Journal of the International AIDS Society, 2017, 20, e25030.	3.0	21
69	Control of HIV-1 by an HLA-B*52:01-C*12:02 Protective Haplotype. Journal of Infectious Diseases, 2017, 216, 1415-1424.	4.0	21
70	Emergence of CXCR4-tropic HIV-1 variants followed by rapid disease progression in hemophiliac slow progressors. PLoS ONE, 2017, 12, e0177033.	2.5	10
71	Colonic cytomegalovirus detection by mucosal PCR and antiviral therapy in ulcerative colitis. PLoS ONE, 2017, 12, e0183951.	2.5	20
72	The second molecular epidemiological study of HIV infection in Mongolia between 2010 and 2016. PLoS ONE, 2017, 12, e0189605.	2.5	7

#	Article	IF	CITATIONS
73	Incidence of syphilis seroconversion among HIVâ€infected persons in Asia: results from the TREAT Asia HIV Observational Database. Journal of the International AIDS Society, 2016, 19, 20965.	3.0	15
74	Incidence of AIDS-Defining Opportunistic Infections and Mortality during Antiretroviral Therapy in a Cohort of Adult HIV-Infected Individuals in Hanoi, 2007-2014. PLoS ONE, 2016, 11, e0150781.	2.5	15
75	High Mortality of Disseminated Non-Tuberculous Mycobacterial Infection in HIV-Infected Patients in the Antiretroviral Therapy Era. PLoS ONE, 2016, 11, e0151682.	2.5	24
76	A strong association of human leukocyte antigen-associated Pol and Gag mutations with clinical parameters in HIV-1 subtype A/E infection. Aids, 2016, 30, 681-689.	2.2	18
77	Urinary β2 microglobulin can predict tenofovir disoproxil fumarate-related renal dysfunction in HIV-1-infected patients who initiate tenofovir disoproxil fumarate-containing antiretroviral therapy. Aids, 2016, 30, 1563-1571.	2.2	19
78	High Plasma Concentrations of Zidovudine (AZT) Do Not Parallel Intracellular Concentrations of AZT-Triphosphates in Infants During Prevention of Mother-to-Child HIV-1 Transmission. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, 246-253.	2.1	4
79	HIV-1 Control by NK Cells via Reduced Interaction between KIR2DL2 and HLA-Câ^—12:02/Câ^—14:03. Cell Reports, 2016, 17, 2210-2220.	6.4	27
80	Prognosis of ocular syphilis in patients infected with HIV in the antiretroviral therapy era. Sexually Transmitted Infections, 2016, 92, 605-610.	1.9	41
81	Brief Report. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, 58-64.	2.1	128
82	Increases in Entamoeba histolytica Antibody–Positive Rates in Human Immunodeficiency Virus–Infected and Noninfected Patients in Japan: A 10-Year Hospital-Based Study of 3,514 Patients. American Journal of Tropical Medicine and Hygiene, 2016, 95, 604-609.	1.4	12
83	Effects of a Single Escape Mutation on T Cell and HIV-1 Co-adaptation. Cell Reports, 2016, 15, 2279-2291.	6.4	19
84	Brief Report. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, 11-14.	2.1	14
85	Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B–Coinfected Adults. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, 294-298.	2.1	55
86	Rilpivirine resistance mutation E138K in HIV-1 reverse transcriptase predisposed by prevalent polymorphic mutations. Journal of Antimicrobial Chemotherapy, 2016, 71, 2760-2766.	3.0	6
87	Novel Conserved-region T-cell Mosaic Vaccine With High Global HIV-1 Coverage Is Recognized by Protective Responses in Untreated Infection. Molecular Therapy, 2016, 24, 832-842.	8.2	107
88	Incidence and Risk Factors for Incident Syphilis among HIV-1-Infected Men Who Have Sex with Men in a Large Urban HIV Clinic in Tokyo, 2008â°'2015. PLoS ONE, 2016, 11, e0168642.	2.5	20
89	Upper Gastrointestinal Symptoms Predictive of Candida Esophagitis and Erosive Esophagitis in HIV and Non-HIV Patients. Medicine (United States), 2015, 94, e2138.	1.0	14
90	Lack of a significant impact of Gag-Protease-mediated HIV-1 replication capacity on clinical parameters in treatment-naive Japanese individuals. Retrovirology, 2015, 12, 98.	2.0	4

#	Article	IF	CITATIONS
91	Ultrasensitive method to quantify intracellular zidovudine monoâ€, di―and triphosphate concentrations in peripheral blood mononuclear cells by liquid chromatography–tandem mass spectrometry. Journal of Mass Spectrometry, 2015, 50, 783-791.	1.6	6
92	Implementation and Operational Research. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 69, e85-e92.	2.1	15
93	Long-Term Trends in Esophageal Candidiasis Prevalence and Associated Risk Factors with or without HIV Infection: Lessons from an Endoscopic Study of 80,219 Patients. PLoS ONE, 2015, 10, e0133589.	2.5	55
94	Routine Eye Screening by an Ophthalmologist Is Clinically Useful for HIV-1-Infected Patients with CD4 Count Less than 200 /1¼L. PLoS ONE, 2015, 10, e0136747.	2.5	27
95	Prevalence of Anal Human Papillomavirus Infection and Risk Factors among HIV-positive Patients in Tokyo, Japan. PLoS ONE, 2015, 10, e0137434.	2.5	27
96	A 21-Day of Adjunctive Corticosteroid Use May Not Be Necessary for HIV-1-Infected Pneumocystis Pneumonia with Moderate and Severe Disease. PLoS ONE, 2015, 10, e0138926.	2.5	5
97	High Treatment Retention Rate in HIV-Infected Patients Receiving Antiretroviral Therapy at Two Large HIV Clinics in Hanoi, Vietnam. PLoS ONE, 2015, 10, e0139594.	2.5	12
98	What Triggers a Diagnosis of HIV Infection in the Tokyo Metropolitan Area? Implications for Preventing the Spread of HIV Infection in Japan. PLoS ONE, 2015, 10, e0143874.	2.5	9
99	HIV-1 infection, but not syphilis or HBV infection, is a strong risk factor for anorectal condyloma in Asian population: A prospective colonoscopy screening study. International Journal of Infectious Diseases, 2015, 37, 70-76.	3.3	4
100	Deconvoluting the Composition of Low-Frequency Hepatitis C Viral Quasispecies: Comparison of Genotypes and NS3 Resistance-Associated Variants between HCV/HIV Coinfected Hemophiliacs and HCV Monoinfected Patients in Japan. PLoS ONE, 2015, 10, e0119145.	2.5	12
101	Different Effects of Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations on Cytotoxic T Lymphocyte Recognition between HIV-1 Subtype B and Subtype A/E Infections. Journal of Virology, 2015, 89, 7363-7372.	3.4	5
102	Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet, The, 2015, 385, 2606-2615.	13.7	521
103	Reply to â€~How does weight influence tenofovir disoproxil-fumarate induced renal function decline?'. Aids, 2015, 29, 645-647.	2.2	0
104	Diagnostic Utility of Quantitative Plasma Cytomegalovirus DNA PCR for Cytomegalovirus End-Organ Diseases in Patients With HIV-1 Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, 140-146.	2.1	18
105	High-Dose Oral Amoxicillin Plus Probenecid Is Highly Effective for Syphilis in Patients With HIV Infection. Clinical Infectious Diseases, 2015, 61, 177-183.	5.8	49
106	Association between a naturally arising polymorphism within a functional region of HIV-1 Nef and disease progression in chronic HIV-1 infection. Archives of Virology, 2015, 160, 2033-2041.	2.1	4
107	Clinical Control of HIV-1 by Cytotoxic T Cells Specific for Multiple Conserved Epitopes. Journal of Virology, 2015, 89, 5330-5339.	3.4	56
108	Fibrocytes Differ from Macrophages but Can Be Infected with HIV-1. Journal of Immunology, 2015, 195, 4341-4350.	0.8	12

#	Article	IF	CITATIONS
109	Long-Term Functional Prognosis of Patients with HIV-Associated Progressive Multifocal Leukoencephalopathy in the Era of Combination ART. AIDS Patient Care and STDs, 2015, 29, 1-3.	2.5	16
110	Drug Transporter Genetic Variants Are Not Associated with TDF-Related Renal Dysfunction in Patients with HIV-1 Infection: A Pharmacogenetic Study. PLoS ONE, 2015, 10, e0141931.	2.5	6
111	Traditional but Not HIV-Related Factors Are Associated with Nonalcoholic Fatty Liver Disease in Asian Patients with HIV-1 Infection. PLoS ONE, 2014, 9, e87596.	2.5	42
112	V3-Independent Competitive Resistance of a Dual-X4 HIV-1 to the CXCR4 Inhibitor AMD3100. PLoS ONE, 2014, 9, e89515.	2.5	2
113	Acute Hepatitis C in HIV-1 Infected Japanese Cohort: Single Center Retrospective Cohort Study. PLoS ONE, 2014, 9, e100517.	2.5	18
114	Trends in First-Line Antiretroviral Therapy in Asia: Results from the TREAT Asia HIV Observational Database. PLoS ONE, 2014, 9, e106525.	2.5	18
115	Single-nucleotide polymorphisms in the UDP-glucuronosyltransferase 1A-3' untranslated region are associated with atazanavir-induced nephrolithiasis in patients with HIV-1 infection: a pharmacogenetic study. Journal of Antimicrobial Chemotherapy, 2014, 69, 3320-3328.	3.0	15
116	Clinical Significance of High Anti-Entamoeba histolytica Antibody Titer in Asymptomatic HIV-1-infected Individuals. Journal of Infectious Diseases, 2014, 209, 1801-1807.	4.0	24
117	Clinical Importance of Hyper-Beta-2-Microglobulinuria in Patients With HIV-1 Infection on Tenofovir-Containing Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, e155-e157.	2.1	3
118	Cumulative exposure to ritonavir-boosted atazanavir is associated with cholelithiasis in patients with HIV-1 infection. Journal of Antimicrobial Chemotherapy, 2014, 69, 1385-1389.	3.0	13
119	Classification of <scp>AIDS</scp> â€related lymphoma cases between 1987 and 2012 in Japan based on the <scp>WHO</scp> classification of lymphomas, fourth edition. Cancer Medicine, 2014, 3, 143-153.	2.8	31
120	Low Prevalence of Transmitted Drug Resistance of HIV-1 During 2008–2012 Antiretroviral Therapy Scaling up in Southern Vietnam. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 66, 358-364.	2.1	14
121	Low Raltegravir Concentration in Cerebrospinal Fluid in Patients With ABCC2 Genetic Variants. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 66, 484-486.	2.1	14
122	Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight. Aids, 2014, 28, 1903-1910.	2.2	62
123	Selection of TI8-8V Mutant Associated with Long-Term Control of HIV-1 by Cross-Reactive HLA-B*51:01–Restricted Cytotoxic T Cells. Journal of Immunology, 2014, 193, 4814-4822.	0.8	11
124	Raltegravir and elvitegravir-resistance mutation E92Q affects HLA-B*40:02-restricted HIV-1-specific CTL recognition. Microbes and Infection, 2014, 16, 434-438.	1.9	1
125	Asymptomatic Intestinal Amebiasis in Japanese HIV-1–Infected Individuals. American Journal of Tropical Medicine and Hygiene, 2014, 91, 816-820.	1.4	10
126	Low body weight and tenofovir use are risk factors for renal dysfunction in Vietnamese HIV-infected patients. A prospective 18-month observation study. Journal of Infection and Chemotherapy, 2014, 20, 784-788.	1.7	13

#	Article	IF	CITATIONS
127	Superimposed Epitopes Restricted by the Same HLA Molecule Drive Distinct HIV-Specific CD8+ T Cell Repertoires. Journal of Immunology, 2014, 193, 77-84.	0.8	15
128	Host-Specific Adaptation of HIV-1 Subtype B in the Japanese Population. Journal of Virology, 2014, 88, 4764-4775.	3.4	47
129	The prevalence of opportunistic infections and malignancies in autopsied patients with human immunodeficiency virus infection in Japan. BMC Infectious Diseases, 2014, 14, 229.	2.9	22
130	Brain Magnetic Resonance Imaging Screening Is Not Useful for HIV-1-Infected Patients Without Neurological Symptoms. AIDS Research and Human Retroviruses, 2014, 30, 970-974.	1.1	7
131	Molecular Basis of a Dominant T Cell Response to an HIV Reverse Transcriptase 8-mer Epitope Presented by the Protective Allele HLA-B*51:01. Journal of Immunology, 2014, 192, 3428-3434.	0.8	25
132	Skin rash induced by ritonavir-boosted darunavir is common, but generally tolerable in an observational setting. Journal of Infection and Chemotherapy, 2014, 20, 285-287.	1.7	8
133	Long-Term Use of Protease Inhibitors Is Associated with Bone Mineral Density Loss. AIDS Research and Human Retroviruses, 2014, 30, 553-559.	1.1	24
134	Impact of HIV Infection on Colorectal Tumors. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 312-317.	2.1	16
135	Incidence and Risk Factors for Incident Hepatitis C Infection Among Men Who Have Sex With Men With HIV-1 Infection in a Large Urban HIV Clinic in Tokyo. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 213-217.	2.1	58
136	DNA methylation profiling can classify HIV-associated lymphomas. Aids, 2014, 28, 503-510.	2.2	11
137	Slow Turnover of HIV-1 Receptors on Quiescent CD4+ T Cells Causes Prolonged Surface Retention of gp120 Immune Complexes In Vivo. PLoS ONE, 2014, 9, e86479.	2.5	4
138	A possible origin of emerged HIV-1 after interrupting anti-retroviral therapy. Biomedical Research, 2014, 35, 1-8.	0.9	2
139	Efforts Against Drug-Resistant Bacteria and Bacteremia in Vietnam. Journal of Disaster Research, 2014, 9, 836-838.	0.7	Ο
140	Assessment of Antigenemia Assay for the Diagnosis of Cytomegalovirus Gastrointestinal Diseases in HIV-Infected Patients. AIDS Patient Care and STDs, 2013, 27, 387-391.	2.5	6
141	Long-term control of CMV retinitis in a patient with idiopathic CD4+ T lymphocytopenia. Journal of Infection and Chemotherapy, 2013, 19, 316-320.	1.7	4
142	Urinary beta-2 microglobulin and alpha-1 microglobulin are useful screening markers for tenofovir-induced kidney tubulopathy in patients with HIV-1 infection: a diagnostic accuracy study. Journal of Infection and Chemotherapy, 2013, 19, 850-857.	1.7	26
143	Combination of high-dose dexamethasone and antiretroviral therapy rapidly improved and induced long-term remission of HIV-related thrombocytopenic purpura. Journal of Infection and Chemotherapy, 2013, 19, 1170-1172.	1.7	3
144	Enteral entrance of Mycobacterium avium in patients with disseminated mycobacterial disease. International Journal of Mycobacteriology, 2013, 2, 121-122.	0.6	2

#	Article	IF	CITATIONS
145	Identification of cross-clade CTL epitopes in HIV-1 clade A/E-infected individuals by using the clade B overlapping peptides. Microbes and Infection, 2013, 15, 874-886.	1.9	15
146	Combined Endoscopy, Aspiration, and Biopsy Analysis for Identifying Infectious Colitis in Patients With Ileocecal Ulcers. Clinical Gastroenterology and Hepatology, 2013, 11, 673-680.e2.	4.4	21
147	Naturally Selected Rilpivirine-Resistant HIV-1 Variants by Host Cellular Immunity. Clinical Infectious Diseases, 2013, 57, 1051-1055.	5.8	22
148	Reply to Tattevin et al. Clinical Infectious Diseases, 2013, 56, 1186-1187.	5.8	1
149	Reply to Hauser et al. Clinical Infectious Diseases, 2013, 56, 166-167.	5.8	1
150	A genome-wide association study of resistance to HIV infection in highly exposed uninfected individuals with hemophilia A. Human Molecular Genetics, 2013, 22, 1903-1910.	2.9	38
151	Evaluation of Combinations of 4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine with Clinically Used Antiretroviral Drugs. Antimicrobial Agents and Chemotherapy, 2013, 57, 4554-4558.	3.2	21
152	WHO Antiretroviral Therapy Guidelines 2010 and Impact of Tenofovir on Chronic Kidney Disease in Vietnamese HIV-Infected Patients. PLoS ONE, 2013, 8, e79885.	2.5	17
153	Prophylactic Effect of Antiretroviral Therapy on Hepatitis B Virus Infection. Clinical Infectious Diseases, 2013, 56, 1812-1819.	5.8	61
154	Distinct HIV-1 Escape Patterns Selected by Cytotoxic T Cells with Identical Epitope Specificity. Journal of Virology, 2013, 87, 2253-2263.	3.4	30
155	Idiopathic Oropharyngeal and Esophageal Ulcers Related to HIV Infection Successfully Treated with Antiretroviral Therapy Alone. Internal Medicine, 2013, 52, 393-395.	0.7	8
156	Epstein-Barr Viral Load in Cerebrospinal Fluid as a Diagnostic Marker of Central Nervous System Involvement of AIDS-related Lymphoma. Internal Medicine, 2013, 52, 955-959.	0.7	21
157	Abacavir/Lamivudine versus Tenofovir/Emtricitabine with Atazanavir/Ritonavir for Treatment-naive Japanese Patients with HIV-1 Infection: A Randomized Multicenter Trial. Internal Medicine, 2013, 52, 735-744.	0.7	14
158	Viral protein R of human immunodeficiency virus type-1 induces retrotransposition of long interspersed element-1. Retrovirology, 2013, 10, 83.	2.0	25
159	Arginine insertion and loss of N-linked glycosylation site in HIV-1 envelope V3 region confer CXCR4-tropism. Scientific Reports, 2013, 3, 2389.	3.3	18
160	Once-daily darunavir/ritonavir and abacavir/lamivudine versus tenofovir/emtricitabine for treatment-naÃ⁻ve patients with a baseline viral load of more than 100 000 copies/ml. Aids, 2013, 27, 839-842.	2.2	7
161	Reply to Sheng et al. Clinical Infectious Diseases, 2013, 57, 1506-1506.	5.8	10
162	Evaluating Immunologic Response and Clinical Deterioration in Treatment-Naive Patients Initiating First-Line Therapies Infected With HIV–1 CRF01_AE and Subtype B. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 293-300.	2.1	16

#	Article	IF	CITATIONS
163	Depression of Local Cell-mediated Immunity and Histological Characteristics of Disseminated AIDS-related <i>Mycobacterium avium</i> Infection after the Initiation of Antiretroviral Therapy. Internal Medicine, 2013, 52, 1793-1803.	0.7	3
164	Potential Function of Granulysin, Other Related Effector Molecules and Lymphocyte Subsets in Patients with TB and HIV/TB Coinfection. International Journal of Medical Sciences, 2013, 10, 1003-1014.	2.5	19
165	Preemptive Therapy Prevents Cytomegalovirus End-Organ Disease in Treatment-NaÃ ⁻ ve Patients with Advanced HIV-1 Infection in the HAART Era. PLoS ONE, 2013, 8, e65348.	2.5	15
166	Illicit Drug Use Is a Significant Risk Factor for Loss to Follow Up in Patients with HIV-1 Infection at a Large Urban HIV Clinic in Tokyo. PLoS ONE, 2013, 8, e72310.	2.5	13
167	Ritonavir-Boosted Darunavir Is Rarely Associated with Nephrolithiasis Compared with Ritonavir-Boosted Atazanavir in HIV-Infected Patients. PLoS ONE, 2013, 8, e77268.	2.5	17
168	Pharmacokinetics of Rifabutin in Japanese HIV-Infected Patients with or without Antiretroviral Therapy. PLoS ONE, 2013, 8, e70611.	2.5	10
169	Factors Associated with Esophageal Candidiasis and Its Endoscopic Severity in the Era of Antiretroviral Therapy. PLoS ONE, 2013, 8, e58217.	2.5	25
170	CD8+ T Cell Cross-Reactivity Profiles and HIV-1 Immune Escape towards an HLA-B35-Restricted Immunodominant Nef Epitope. PLoS ONE, 2013, 8, e66152.	2.5	6
171	Is Ritonavir-Boosted Atazanavir a Risk for Cholelithiasis Compared to Other Protease Inhibitors?. PLoS ONE, 2013, 8, e69845.	2.5	10
172	Switching Tenofovir/Emtricitabine plus Lopinavir/r to Raltegravir plus Darunavir/r in Patients with Suppressed Viral Load Did Not Result in Improvement of Renal Function but Could Sustain Viral Suppression: A Randomized Multicenter Trial. PLoS ONE, 2013, 8, e73639.	2.5	34
173	High Prevalence of Illicit Drug Use in Men Who Have Sex with Men with HIV-1 Infection in Japan. PLoS ONE, 2013, 8, e81960.	2.5	17
174	Diagnostic value of endothelial markers and HHV-8 staining in gastrointestinal Kaposi sarcoma and its difference in endoscopic tumor staging. World Journal of Gastroenterology, 2013, 19, 3608.	3.3	6
175	Endoscopic appearance of AIDS-related gastrointestinal lymphoma with c- <i>MYC</i> rearrangements: Case report and literature review. World Journal of Gastroenterology, 2013, 19, 4827.	3.3	9
176	Side Effect of Efavirenz and CYP2B6*6/*6. Japanese Journal of Clinical Pharmacology and Therapeutics, 2013, 44, 233-233.	0.1	0
177	False-Negative Results of Endoscopic Biopsy in the Diagnosis of Gastrointestinal Kaposi's Sarcoma in HIV-Infected Patients. Pathology Research International, 2012, 2012, 1-6.	1.4	6
178	Single Nucleotide Polymorphisms in ABCC2 Associate With Tenofovir-Induced Kidney Tubular Dysfunction in Japanese Patients With HIV-1 Infection: A Pharmacogenetic Study. Clinical Infectious Diseases, 2012, 55, 1558-1567.	5.8	72
179	HLA Class I-Mediated Control of HIV-1 in the Japanese Population, in Which the Protective HLA-B*57 and HLA-B*27 Alleles Are Absent. Journal of Virology, 2012, 86, 10870-10872.	3.4	40
180	Selection and Accumulation of an HIV-1 Escape Mutant by Three Types of HIV-1-Specific Cytotoxic T Lymphocytes Recognizing Wild-Type and/or Escape Mutant Epitopes. Journal of Virology, 2012, 86, 1971-1981.	3.4	15

#	Article	IF	CITATIONS
181	HIV-1 Reverse Transcriptase (RT) Polymorphism 172K Suppresses the Effect of Clinically Relevant Drug Resistance Mutations to Both Nucleoside and Non-nucleoside RT Inhibitors. Journal of Biological Chemistry, 2012, 287, 29988-29999.	3.4	9
182	High Incidence of Renal Stones Among HIV-Infected Patients on Ritonavir-Boosted Atazanavir Than in Those Receiving Other Protease Inhibitor-Containing Antiretroviral Therapy. Clinical Infectious Diseases, 2012, 55, 1262-1269.	5.8	80
183	Outbreaks of Pneumocystis Pneumonia in 2 Renal Transplant Centers Linked to a Single Strain of Pneumocystis: Implications for Transmission and Virulence. Clinical Infectious Diseases, 2012, 54, 1437-1444.	5.8	67
184	Differential Clade-Specific HLA-B*3501 Association with HIV-1 Disease Outcome Is Linked to Immunogenicity of a Single Gag Epitope. Journal of Virology, 2012, 86, 12643-12654.	3.4	49
185	Epstein–Barr virus associated colitis in an HIV-infected patient. Aids, 2012, 26, 400-402.	2.2	5
186	Blunted fetal growth by tenofovir in late pregnancy. Aids, 2012, 26, 2119-2120.	2.2	10
187	Efficacy and safety of once-daily ritonavir-boosted darunavir and abacavir/lamivudine for treatment-naÃ ⁻ ve patients. Aids, 2012, 26, 649-651.	2.2	7
188	FDG Uptake by a Condylomata Acuminata in an HIV-Infected Patient Mimicked Urine Contamination. Clinical Nuclear Medicine, 2012, 37, 420-421.	1.3	6
189	Infectious Endocarditis Caused by <i>Lactobacillus acidophilus</i> in a Patient with Mistreated Dental Caries. Internal Medicine, 2012, 51, 1619-1621.	0.7	12
190	Drug-Induced Acute Interstitial Nephritis Mimicking Acute Tubular Necrosis after Initiation of Tenofovir-Containing Antiretroviral Therapy in Patient with HIV-1 Infection. Internal Medicine, 2012, 51, 2469-2471.	0.7	6
191	Trends in early and late diagnosis of HIV-1 infections in Tokyoites from 2002 to 2010. International Journal of Infectious Diseases, 2012, 16, e172-e177.	3.3	4
192	Minor contribution of HLA class I-associated selective pressure to the variability of HIV-1 accessory protein Vpu. Biochemical and Biophysical Research Communications, 2012, 421, 291-295.	2.1	9
193	<pre><scp>CTL</scp> recognition of <scp>HIV</scp>â€lâ€infected cells via crossâ€recognition of multiple overlapping peptides from a single 11â€mer <scp>P</scp>ol sequence. European Journal of Immunology, 2012, 42, 2621-2631.</pre>	2.9	5
194	Diagnostic accuracy of indirect immunofluorescence assay for intestinal invasive amebiasis and impact of HIV infection in a non-endemic country. Diagnostic Microbiology and Infectious Disease, 2012, 74, 374-378.	1.8	5
195	Renal Function Declines More in Tenofovir- than Abacavir-Based Antiretroviral Therapy in Low-Body Weight Treatment-NaÃ ⁻ ve Patients with HIV Infection. PLoS ONE, 2012, 7, e29977.	2.5	54
196	Predictive Clinical Factors in the Diagnosis of Gastrointestinal Kaposi's Sarcoma and Its Endoscopic Severity. PLoS ONE, 2012, 7, e46967.	2.5	36
197	Risk Factors for Intestinal Invasive Amebiasis in Japan, 2003–2009. Emerging Infectious Diseases, 2012, 18, 717-724.	4.3	51
198	Failure to prescribe pneumocystis prophylaxis is associated with increased mortality, even in the cART era: results from the Treat Asia HIV observational database. Journal of the International AIDS Society, 2012, 15, 1-1.	3.0	92

#	Article	IF	CITATIONS
199	Kaposi's Sarcoma Presenting as a Bulky Tumor Mass of the Colon. Clinical Gastroenterology and Hepatology, 2011, 9, A22.	4.4	4
200	The high mannose-type glycan binding lectin actinohivin: dimerization greatly improves anti-HIV activity. Journal of Antibiotics, 2011, 64, 551-557.	2.0	12
201	Identification of a Current Hot Spot of HIV Type 1 Transmission in Mongolia by Molecular Epidemiological Analysis. AIDS Research and Human Retroviruses, 2011, 27, 1073-1080.	1.1	11
202	Diagnostic value of antigenemia assay for cytomegalovirus gastrointestinal disease in immunocompromised patients. World Journal of Gastroenterology, 2011, 17, 1185.	3.3	30
203	K70Q Adds High-Level Tenofovir Resistance to "Q151M Complex―HIV Reverse Transcriptase through the Enhanced Discrimination Mechanism. PLoS ONE, 2011, 6, e16242.	2.5	29
204	Antiretroviral therapy alone resulted in successful resolution of large idiopathic esophageal ulcers in a patient with acute retroviral syndrome. Aids, 2011, 25, 1677-1679.	2.2	9
205	Living Donor Liver Transplantations in HIV- and Hepatitis C Virus-Coinfected Hemophiliacs: Experience in a Single Center. Transplantation, 2011, 91, 1261-1264.	1.0	24
206	Clinical Symptoms and Courses of Primary HIV-1 Infection in Recent Years in Japan. Internal Medicine, 2011, 50, 95-101.	0.7	9
207	Open-Label Randomized Multicenter Selection Study of Once Daily Antiretroviral Treatment Regimen Comparing Ritonavir-Boosted Atazanavir to Efavirenz with Fixed-Dose Abacavir and Lamivudine. Internal Medicine, 2011, 50, 699-705.	0.7	10
208	Prevalence of and risk factors for lipodystrophy among HIV-infected patients receiving combined antiretroviral treatment in the Asia-Pacific region: results from the TREAT Asia HIV Observational Database (TAHOD). Endocrine Journal, 2011, 58, 475-484.	1.6	19
209	Primary HIV Infection with Acute Transverse Myelitis. Internal Medicine, 2011, 50, 1615-1617.	0.7	20
210	Antiretroviral Therapy for Treatment-naieve Chronic HIV-1 Infection with an Axonal Variant of Guillain-Barre Syndrome Positive for Anti-ganglioside Antibody: A Case Report. Internal Medicine, 2011, 50, 2427-2429.	0.7	9
211	<i>>MYCOBACTERIUM LENTIFLAVUM</i> ILEITIS USING ASPIRATED INTESTINAL FLUID DURING ENDOSCOPY IN HIVâ€INFECTED PATIENT. Digestive Endoscopy, 2011, 23, 271-272.	2.3	6
212	Selection of escape mutant by HLAâ€Câ€restricted HIVâ€1 Polâ€specific cytotoxic T lymphocytes carrying strong ability to suppress HIVâ€1 replication. European Journal of Immunology, 2011, 41, 97-106.	2.9	26
213	Effective recognition of HIV-1-infected cells by HIV-1 integrase-specific HLA-Bâ^—4002-restricted T cells. Microbes and Infection, 2011, 13, 160-166.	1.9	10
214	Selection of HLA-B57-associated Gag A146P mutant by HLA-Bâ^—48:01-restricted Gag140-147-specific CTLs in chronically HIV-1-infected Japanese. Microbes and Infection, 2011, 13, 766-770.	1.9	3
215	Case of relapsed AIDS-related plasmablastic lymphoma treated with autologous stem cell transplantation and highly active antiretroviral therapy. Rare Tumors, 2011, 3, 33-35.	0.6	9
216	Paediatric HIV and elimination of mother-to-child transmission of HIV in the ASEAN region: a call to action. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2011, 23, 413-416.	1.2	3

#	Article	IF	CITATIONS
217	Amebiasis in HIV-1-Infected Japanese Men: Clinical Features and Response to Therapy. PLoS Neglected Tropical Diseases, 2011, 5, e1318.	3.0	56
218	Impact of Small Body Weight on Tenofovir-Associated Renal Dysfunction in HIV-Infected Patients: A Retrospective Cohort Study of Japanese Patients. PLoS ONE, 2011, 6, e22661.	2.5	92
219	Raltegravir-associated perihepatitis and peritonitis: a single case report. Aids, 2010, 24, 160-161.	2.2	7
220	Impact of human leukocyte antigen-B*51-restricted cytotoxic T-lymphocyte pressure on mutation patterns of nonnucleoside reverse transcriptase inhibitor resistance. Aids, 2010, 24, F15-F22.	2.2	13
221	Trends in transmitted drug-resistant HIV-1 and demographic characteristics of newly diagnosed patients: Nationwide surveillance from 2003 to 2008 in Japan. Antiviral Research, 2010, 88, 72-79.	4.1	50
222	Multiple routes of hepatitis C virus transmission among injection drug users in Hai Phong, Northern Vietnam. Journal of Medical Virology, 2010, 82, 1355-1363.	5.0	26
223	Comparison of CD4+ T-cell subset distribution in chronically infected HIV+ patients with various CD4 nadir counts. Microbes and Infection, 2010, 12, 374-381.	1.9	12
224	Impact of CRF01_AE-specific polymorphic mutations G335D and A371V in the connection subdomain of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on susceptibility to nucleoside RT inhibitors. Microbes and Infection, 2010, 12, 1170-1177.	1.9	18
225	Trends in CD4 counts in HIV-infected patients with HIV viral load monitoring while on combination antiretroviral treatment: results from The TREAT Asia HIV Observational Database. BMC Infectious Diseases, 2010, 10, 361.	2.9	22
226	Reply to del Palacio et al. Clinical Infectious Diseases, 2010, 50, 452-453.	5.8	1
227	Combination of V106I and V179D Polymorphic Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confers Resistance to Efavirenz and Nevirapine but Not Etravirine. Antimicrobial Agents and Chemotherapy, 2010, 54, 1596-1602.	3.2	31
228	Different <i>In Vivo</i> Effects of HIV-1 Immunodominant Epitope-Specific Cytotoxic T Lymphocytes on Selection of Escape Mutant Viruses. Journal of Virology, 2010, 84, 5508-5519.	3.4	12
229	Characterization of HIV Type 1 Genotypes and Drug Resistance Mutations Among Drug-Naive HIV Type 1-Infected Patients in Northern Vietnam. AIDS Research and Human Retroviruses, 2010, 26, 233-235.	1.1	15
230	Long-Term Control of HIV-1 in Hemophiliacs Carrying Slow-Progressing Allele HLA-B*5101. Journal of Virology, 2010, 84, 7151-7160.	3.4	42
231	Autoimmune Diabetes in HIV-Infected Patients on Highly Active Antiretroviral Therapy. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 4056-4060.	3.6	32
232	Selection of escape mutation by Pol154-162-specific cytotoxic T cells among chronically HIV-1-infected HLA-B*5401-positive individuals. Human Immunology, 2010, 71, 123-127.	2.4	2
233	Naturally arising HIV-1 Nef variants conferring escape from cytotoxic T lymphocytes influence viral entry co-receptor expression and susceptibility to superinfection. Biochemical and Biophysical Research Communications, 2010, 403, 422-427.	2.1	9
234	Introduction of TaqMan HIV-1 Assay Increased Unnecessary Drug Resistance Testing. AIDS Patient Care and STDs, 2010, 24, 203-204.	2.5	1

#	Article	IF	CITATIONS
235	Allele and Genotype Frequencies of <i>Cytochrome P450 2B6</i> Gene in a Mongolian Population. Drug Metabolism and Disposition, 2009, 37, 1991-1993.	3.3	17
236	Detection of HIV Type 1 Load by the Roche Cobas TaqMan Assay in Patients with Viral Loads Previously Undetectable by the Roche Cobas Amplicor Monitor. Clinical Infectious Diseases, 2009, 48, 260-262.	5.8	42
237	Strong Ability of Nef-Specific CD4 ⁺ Cytotoxic T Cells To Suppress Human Immunodeficiency Virus Type 1 (HIV-1) Replication in HIV-1-Infected CD4 ⁺ T Cells and Macrophages. Journal of Virology, 2009, 83, 7668-7677.	3.4	40
238	Serum (1→3) βâ€ <scp>d</scp> â€Glucan as a Noninvasive Adjunct Marker for the Diagnosis of <i>Pneumocystis</i> Pneumonia in Patients with AIDS. Clinical Infectious Diseases, 2009, 49, 1128-1131.	5.8	86
239	Shortâ€Term Clinical Disease Progression in HIVâ€Infected Patients Receiving Combination Antiretroviral Therapy: Results from the TREAT Asia HIV Observational Database. Clinical Infectious Diseases, 2009, 48, 940-950.	5.8	25
240	TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories. Journal of Virological Methods, 2009, 159, 185-193.	2.1	35
241	Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naÃ ⁻ ve patients. Antiviral Research, 2009, 82, 115-121.	4.1	38
242	High frequency and proliferation of CD4 ⁺ FOXP3 ⁺ Treg in HIVâ€1â€infected patients with low CD4 counts. European Journal of Immunology, 2009, 39, 301-309.	2.9	63
243	Risk and prognostic significance of tuberculosis in patients from The TREAT Asia HIV Observational Database. BMC Infectious Diseases, 2009, 9, 46.	2.9	27
244	Adaptation of HIV-1 to human leukocyte antigen class I. Nature, 2009, 458, 641-645.	27.8	408
245	Escape mutation selected by Gag28-36-specific cytotoxic T cells in HLA-A*2402-positive HIV-1-infected donors. Microbes and Infection, 2009, 11, 198-204.	1.9	7
246	Profile of HIV Type 1 Infection and Genotypic Resistance Mutations to Antiretroviral Drugs in Treatment-Naive HIV Type 1-Infected Individuals in Hai Phong, Viet Nam. AIDS Research and Human Retroviruses, 2009, 25, 175-182.	1.1	30
247	Identification and characterization of 2 HIV-1 Gag immunodominant epitopes restricted by Asian HLA allele HLA-B*4801. Human Immunology, 2009, 70, 170-174.	2.4	5
248	Outbreak of Pneumocystis jiroveci Pneumonia in Renal Transplant Recipients: P. jiroveci Is Contagious to the Susceptible Host. Transplantation, 2009, 88, 380-385.	1.0	101
249	Successful genotype-tailored treatment with small-dose efavirenz. Aids, 2009, 23, 433-434.	2.2	16
250	Autologous Stem Cell Transplantation using MEAM Regimen for Relapsed AIDS-Related Lymphoma Patients Who Received Highly Active Anti-Retroviral Therapy: A Report of Three Cases. Internal Medicine, 2009, 48, 111-114.	0.7	9
251	Successful Absorption of Antiretroviral Drugs after Gastrojejunal Bypass Surgery following Failure of Therapy through a Jejunal Tube. Internal Medicine, 2009, 48, 1103-1104.	0.7	23
252	Successful Treatment of Ulcerous Skin Lesion Caused by Mistaken Intradermal Injection of BCG (Bacille de Calmette et Guerin) Vaccine with Anti-tuberculous Drugs and Systemic Administration of Corticosteroid. Internal Medicine, 2009, 48, 1323-1325.	0.7	2

#	Article	IF	CITATIONS
253	HLA-A*2402-restricted HIV-1-specific cytotoxic T lymphocytes and escape mutation after ART with structured treatment interruptions. Microbes and Infection, 2008, 10, 689-698.	1.9	8
254	Identification and characterization of HLA-B*5401-restricted HIV-1-Nef and Pol-specific CTL epitopes. Microbes and Infection, 2008, 10, 764-772.	1.9	11
255	Different Abilities of Escape Mutant-Specific Cytotoxic T Cells To Suppress Replication of Escape Mutant and Wild-Type Human Immunodeficiency Virus Type 1 in New Hosts. Journal of Virology, 2008, 82, 138-147.	3.4	32
256	CTL-Mediated Selective Pressure Influences Dynamic Evolution and Pathogenic Functions of HIV-1 Nef. Journal of Immunology, 2008, 180, 1107-1116.	0.8	57
257	Amino Acid Mutation N348I in the Connection Subdomain of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confers Multiclass Resistance to Nucleoside and Nonnucleoside Reverse Transcriptase Inhibitors. Journal of Virology, 2008, 82, 3261-3270.	3.4	88
258	Pharmacogenetic information derived from analysis of <i>HLA</i> alleles. Pharmacogenomics, 2008, 9, 207-214.	1.3	33
259	Altering Effects of Antigenic Variations in HIV-1 on Antiviral Effectiveness of HIV-Specific CTLs. Journal of Immunology, 2007, 178, 5513-5523.	0.8	33
260	Successful Efavirenz Dose Reduction in HIV Type 1-Infected Individuals with Cytochrome P450 2B6 *6 and *26. Clinical Infectious Diseases, 2007, 45, 1230-1237.	5.8	210
261	Prevalence of coinfection with human immunodeficiency virus and hepatitis C virus in Japan. Hepatology Research, 2007, 37, 2-5.	3.4	22
262	Drug-resistant HIV-1 prevalence in patients newly diagnosed with HIV/AIDS in Japanâ~†. Antiviral Research, 2007, 75, 75-82.	4.1	46
263	Performance and quality assurance of genotypic drug-resistance testing for human immunodeficiency virus type 1 in Japan. Japanese Journal of Infectious Diseases, 2007, 60, 113-7.	1.2	13
264	Decrease in Epstein–Barr virus-positive AIDS-related lymphoma in the era of highly active antiretroviral therapy. Microbes and Infection, 2006, 8, 1301-1307.	1.9	18
265	Mutations other than 103N in human immunodeficiency virus type 1 reverse transcriptase (RT) emerge from K103R polymorphism under non-nucleoside RT inhibitor pressure. Virology, 2006, 344, 354-362.	2.4	23
266	Urinaryβ2-Microglobulin as a Possible Sensitive Marker for Renal Injury Caused by Tenofovir Disoproxil Fumarate. AIDS Research and Human Retroviruses, 2006, 22, 744-748.	1.1	93
267	Patterns of Cytokine Production in Human Immunodeficiency Virus Type 1 (HIV-1)-Specific Human CD8 + T Cells after Stimulation with HIV-1-Infected CD4 + T Cells. Journal of Virology, 2005, 79, 12536-12543.	3.4	10
268	Cutting Edge: Epitope-Dependent Effect of Nef-Mediated HLA Class I Down-Regulation on Ability of HIV-1-Specific CTLs to Suppress HIV-1 Replication. Journal of Immunology, 2005, 174, 36-40.	0.8	51
269	Identification and Characterization of HIV-1 Epitopes Presented by HLA-A*2603: Comparison Between HIV-1 Epitopes Presented by A*2601 and A*2603. Human Immunology, 2005, 66, 1155-1166.	2.4	5
270	Functionally Impaired HIV-Specific CD8 T Cells Show High Affinity TCR-Ligand Interactions. Journal of Immunology, 2004, 173, 5451-5457.	0.8	51

#	Article	IF	CITATIONS
271	Novel patterns of nevirapine resistance-associated mutations of human immunodeficiency virus type 1 in treatment-naÃ ⁻ ve patients. Virology, 2004, 327, 215-224.	2.4	16
272	Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochemical and Biophysical Research Communications, 2004, 319, 1322-1326.	2.1	257
273	"All-in-One Assayâ€; a direct phenotypic anti-human immunodeficiency virus type 1 drug resistance assay for three-drug combination therapies that takes into consideration in vivo drug concentrations. Journal of Virological Methods, 2003, 111, 43-53.	2.1	6
274	Identification and Characterization of HLA-A*3303-Restricted, HIV Type 1 Pol- and Gag-Derived Cytotoxic T Cell Epitopes. AIDS Research and Human Retroviruses, 2003, 19, 503-510.	1.1	14
275	Dilated Cardiomyopathy in an Adult Human Immunodeficiency Virus Type 1-Positive Patient Treated with a Zidovudine-Containing Antiretroviral Regime. Clinical Infectious Diseases, 2003, 37, e109-e111.	5.8	27
276	Cytotoxic T-cell recognition of HIV-1 cross-clade and clade-specific epitopes in HIV-1-infected Thai and Japanese patients. Aids, 2002, 16, 701-711.	2.2	26
277	Rapid and Simple Phenotypic Assay for Drug Susceptibility of Human Immunodeficiency Virus Type 1 Using CCR5-Expressing HeLa/CD4 + Cell Clone 1-10 (MAGIC-5). Antimicrobial Agents and Chemotherapy, 2001, 45, 495-501.	3.2	86
278	Diagnosis and Monitoring of Human Cytomegalovirus Diseases in Patients with Human Immunodeficiency Virus Infection by Use of a Real‶ime PCR Assay. Clinical Infectious Diseases, 2001, 33, 1756-1761.	5.8	19
279	Augmentation of Human Immunodeficiency Virus Type 1 Subtype E (CRF01_AE) Multiple-Drug Resistance by Insertion of a Foreign 11-Amino-Acid Fragment into the Reverse Transcriptase. Journal of Virology, 2001, 75, 5604-5613.	3.4	30
280	Identification of multiple HIV-1 CTL epitopes presented by HLA-Bâ^—5101 molecules. Human Immunology, 1999, 60, 177-186.	2.4	45
281	Detection of Toxoplasma gondii, Epstein-Barr Virus, and JC Virus DNAs in the Cerebrospinal Fluid in Acquired Immunodeficiency Syndrome Patients with Focal Central Nervous System Comlications	0.7	40